ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prevention"

  • Abstract Number: 2285 • ACR Convergence 2023

    Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update

    J. Patricia Dhar1, Hannah Forsythe2, Louis Saravolatz1 and Susanna Szpunar3, 1Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, 2Michigan Department of Human and Health Services, Lansing, MI, 3Ascension St. John Hospital, Detroit, MI

    Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
  • Abstract Number: 1089 • ACR Convergence 2023

    Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic

    Nagendra Pokala1, Benjamin Gardner2, Avni Amratia1, Daniel Emesiani3, Jiby Mathew4, Rashmi Arora5, Una Makris6 and Swathi Reddy7, 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 2Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, 3Baylor Scott and White Medical Center McKinney, Dallas, TX, 4VA North Texas Healthcare System, Dallas, TX, 5Department of Internal Medicine, UT Southwestern Medical Center; VA North Texas Healthcare System, Dallas, TX, 6UT Southwestern Medical Center and Dallas VA, Dallas, TX, 7UT Southwestern Medical Center / Dallas VA Medical Center, Colleyville, TX

    Background/Purpose: Due in part to immunosuppressant medications, patients with rheumatic diseases not only carry a higher risk of herpes zoster reactivation but also worse outcomes.…
  • Abstract Number: 2490 • ACR Convergence 2023

    Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial

    Junna Ye1, Yijun You2, Zhuochao Zhou2, Jingyi Wu2, Fan wang2 and Chengde Yang2, 1Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…
  • Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium

    COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey

    Beth Rutstein1, Merav Heshin Bekenstein2, Maria Schletzbaum3, Nora Singer4, Rebecca Sadun5, Melanie Kohlheim6, Vincent Del Gaizo7, Kelly Wise8, Melica Nikahd9, Guy Brock9, Monica Ardura8, Vidya Sivaraman10 and For the CARRA Investigators11, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Tel Aviv Medical Center, Tel Aviv, Israel, 3Medical College of Wisconsin, Milwaukee, WI, 4Metro Health, Cleveland, OH, 5Duke University, Durham, NC, 6None, Columbus, OH, 7CARRA, Washington, DC, 8Nationwide Children's Hospital, Columbus, OH, 9The Ohio State University, Columbus, OH, 10Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 11Duke University Medical Center, Durham, NC

    Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
  • Abstract Number: L08 • ACR Convergence 2022

    Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders

    Christopher Podgorski1 and Deborah Parks2, 1BJC/Washington University Consortium, St. Louis, MO, 2Washington University/B-JH/SLCH Consortium, St. Louis, MO

    Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…
  • Abstract Number: L16 • ACR Convergence 2022

    Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)

    Benjamin Terrier1, Laura Richert2, Grégory Pugnet3, Olivier Aumaitre4, Olivier Moranne5, Elisabeth Diot6, Alexandre Karras7, Fabrice Bonnet8, Claire De Moreuil9, Eric Hachulla10, Thomas Le Gallou11, Céline Lebas10, Francois Maurier12, Cédric Rafat7, Maxime Samson13, Jean-Francois Augusto14, Grégoire Couvrat-Devergne15, Cécile Janssen16, Thierry Martin17, Thomas Quemeneur18, Pierre-Louis Caron19, Cécile-Audrey Durel20, Khalil El Karoui7, Aurélie Grados21, Mathieu Puyade22, Virginie Rieu4, Yurdagul Uzunhan23, Jean-Francois Viallard8, Xavier Puéchal7, Loic Guillevin7, Noémie Huchet8, Hendy Abdoul7, Carine Bellera8, Frédéric Batteux7 and Odile Launay7, 1Cochin Hospital, Paris, France, 2EUCLID, Bordeaux, France, 3CHU, Toulouse, France, 4CHU, Clermont-Ferrand, France, 5CHU, Nimes, France, 6CHU, Tours, France, 7CHU, Paris, France, 8CHU, Bordeaux, France, 9CHU, Brest, France, 10CHU, Lille, France, 11CHU, Rennes, France, 12CH, Metz, France, 13CHU, Dijon, France, 14CHU, Angers, France, 15CH, La Roche sur Yon, France, 16CH, Annecy, France, 17CHU, Strasbourg, France, 18CH, Valenciennes, France, 19CHU, Grenoble, France, 20CHU, Lyon, France, 21CH, Niot, France, 22CHU, Poitiers, France, 23CHU, Bobigny, France

    Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
  • Abstract Number: 0616 • ACR Convergence 2022

    Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes

    Liam O'Neil1, XIAOBO MENG1, Caitin McFadyen1, Marvin Fritzler2 and Hani El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Calgary, Calgary, AB, Canada

    Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
  • Abstract Number: 1323 • ACR Convergence 2022

    Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time

    JOSE ELOY OLLER RODRIGUEZ1, Elena Grau García2, Samuel Leal Rodriguez3, Laura Mas Sanchez2, Pablo Francisco Muñoz Martínez4, Carmen Riesco Bárcena5, Anderson Huaylla Quispe6, Cristobal Pavez Perales2, Francisco Miguel Ortiz Sanjuan7, José Ivorra Cortés2, Inés Cánovas Olmos2, Luis González Puig8, Isabel Martínez-Cordellat2, Carmen Nájera Herranz7, Rosa Negueroles Albuixech2, Elvira Vicens Bernabeu7, Alba Torrat Novés5, Daniel Ramos Castro2 and José andrés Román ivorra3, 1Hospital Universitario de La Fe, València, Spain, 2Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, 3Hospital Universitari i Politécnic La Fe, València, Spain, 4Hospital Universitario y Politécnico La Fe, València, Spain, 5Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, 6Medicina, València, Spain, 7Hospital Universitario de La Fe, València, 8Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain

    Background/Purpose: Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral…
  • Abstract Number: 0703 • ACR Convergence 2022

    Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry

    Jose A Gomez-Puerta1, Ana Lúcia Martins Fernandes2, Juan Camilo Sarmiento-Monroy1, Saskia Lawson-Tovey3, Kimme Hyrich4, Laure Gossec5, Loreto Carmona6, Anja Strangfeld7, Elsa Mateus8, Ana Maria Rodrigues9, Eric Hachulla10, Marta Mosca11, Patrick Durez12, Bernd Raffeiner13, Nicolas Roux14, Viellard Eric15, Olivier Brocq16, Julija Zepa17, Eva Strakova18, Inita Bulina19, Vanda Mlynarikova20, Emoke Šteňová21, Martin Soubrier22, Xavier Mariette23 and Pedro Machado24, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Centro Hospitalar Universitário do Algarve, Faro, Portugal, 3Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4The University of Manchester, Manchester, United Kingdom, 5Sorbonne Université, Paris, France, 6Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 7Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 8EULAR, Lisboa, Portugal, 9Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, 10University of Lille, LILLE, France, 11Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 12Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 13Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, 14Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, 15Private practice, St. Malo, France, 16Rheumatology- CH Princesse Grace, Monaco, Monaco, 17Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, 18Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, 19Pauls Stradins Clinical University Hospital, Riga, Riga, Latvia, 20National Institute of Rheumatic Diseases, Piešťany, Slovakia, 21University Hospital, Bratislava, Slovakia, 22Gabriel-Montpied Hospital, Clermont-Ferrand, France, 23Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 24University College London, London, United Kingdom

    Background/Purpose: Some concerns have been raised with the use of vaccines against SARS-CoV-2 in patients with Systemic Autoimmune Diseases (SAD) including the risk of serious…
  • Abstract Number: 1391 • ACR Convergence 2022

    Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis

    Tooba Munawar1, Farzam Khokhar2 and Andras Perl3, 1SUNY Upstate Medical Unviersity, Jamesville, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3SUNY, Syracuse, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Patients with RA are at risk of accelerated cardiovascular disease (CVD). The purpose of this study…
  • Abstract Number: 0720 • ACR Convergence 2022

    Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study

    Jun Won Park1, Jeffrey Curtis2, Min Jung Kim3, You-Jung Ha4, Yun Jong Lee4 and Eun Bong Lee1, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, 4Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
  • Abstract Number: 1596 • ACR Convergence 2022

    The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk

    Sarah Stoots1, Joshua Baker1 and Joan Von Feldt2, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Wilmington, DE

    Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator…
  • Abstract Number: 0727 • ACR Convergence 2022

    Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System

    Eugene Looi1, Gergana Mishkova1 and Christina Downey2, 1Loma Linda University, Loma Linda, CA, 2Loma Linda University Medical Center, Redlands, CA

    Background/Purpose: Osteoporosis (OSP) is common, carries high morbidity, significant cost and remains underrecognized and undertreated by health care providers (1). At a university-based academic health…
  • Abstract Number: 1603 • ACR Convergence 2022

    Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial

    Doortje Krijbolder1, Marloes Verstappen1, Bastiaan van Dijk2, Yousra Dakkak1, Aleid Boer1, Yune-Jung Park1, Marianne E. de Witt-Luth3, Karen Visser4, Marc Kok5, Esmeralda T.H. Molenaar6, Pascal de Jong7, Stephan Böhringer8, Tom Huizinga1, CF Allaart1, Ellis Niemantsverdriet9 and Annette van der Helm-van Mil10, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre (LUMC), Leiden, Netherlands, 3Reinier de Graaf Ziekenhuis, Delft, Netherlands, 4Haga Ziekenhuis, Amsterdam, Netherlands, 5Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, 6Groene Hart Ziekenhuis, Gouda, Netherlands, 7ErasmusMC, Hendrik Ido Ambacht, Netherlands, 8Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, 9LUMC, Leiden, Netherlands, 10Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and requires long term treatment to suppress inflammation. Currently, treatment is started when arthritis is…
  • Abstract Number: 0781 • ACR Convergence 2022

    Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose

    Daniel Magliulo1, Vasileios Kyttaris1 and Emily Rose2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, West Roxbury, MA

    Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology